Heat shock protein 90 targeting therapy: State of the art and future perspective

EXCLI Journal

Volumn 14, Issue , 2015, Pages 48-58

  Tatokoro, Manabu ^a   Koga, Fumitaka ^b   Yoshida, Soichiro ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Bladder cancer; Cancer; Clinical trial; Hsp90 inhibitor

Indexed keywords

ALVESPIMYCIN; BORTEZOMIB; CRIZOTINIB; DOCETAXEL; ERLOTINIB; FULVESTRANT; GANETESPIB; IRINOTECAN; LUMINESPIB; PACLITAXEL; PEMETREXED; PLACEBO; PLERIXAFOR; QUIZARTINIB; RAPAMYCIN; RETASPIMYCIN; TANESPIMYCIN; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ANOREXIA; BLADDER CANCER CELL LINE; BLADDER CANCER INITIATING CELL; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASTRATION REFRACTORY PROSTATE CANCER; CASTRATION RESISTANT PROSTATE CANCER; CHEMORADIOTHERAPY; CHONDROSARCOMA; COLON CANCER; DIARRHEA; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; EYE TOXICITY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC DISEASE; HER2 POSITIVE BREAST CANCER; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MELANOMA; METASTATIC MELANOMA; METASTATIC PANCREAS CANCER; METASTATIC PANCREATIC CANCER; MULTIPLE MYELOMA; MUSCLE INVASIVE BLADDER CANCER; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NON SMALL CELL LUNG CANCER; OCULAR MELANOMA; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PLATINUM RESISTANT OVARIAN CANCER; PLEURA MESOTHELIOMA; PROSTATE CANCER; RECTUM CANCER; REVIEW; SMALL CELL LUNG CANCER; STOMACH CANCER; UTERINE TUBE TUMOR; VOMITING;

EID: 84922032675     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: 10.17179/excli2014-586     Document Type: Review

References (61)

1. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17- allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 2003;63:8984-95.
2. Buchner J. Hsp90 & Co. - a holding for folding. Trends Biochem Sci. 1999;24:136-41.
3. Chen B, Piel WH, Gui L, Bruford E, Monteiro A. The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics. 2005;86:627-37.
4. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84.
5. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot (Tokyo). 1970;23:442-7.
6. Demetri GD, Le Cesne A, Von Mehren M, Chmielowski B, Bauer S, Chow WA, et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. 2010 Gastrointestinal Cancers Symposium. 2010. http://meetinglibrary.asco.org/content/2285-72.
7. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino) ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDAMB- 231 human breast cancer xenografts. Cancer Chemother Pharmacol. 2005;55:21-32.
8. Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, et al. Novel Hsp90 inhibitor NVPAUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther. 2013;14:347-56.
9. Garon EB, Moran T, Bariesi F, Gandhi L, Sequist LV, Kim S-W, et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 30, 2012;30(Suppl):abstr 7543.
10. Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, et al. A phase II study of 17- allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 2012;131:933-7.
11. Goss GD, Manegold C, Rosell R, Fennell FD, Vukovic VM, El-Hariry I, et al.The GALAXY trial (NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIB or IV NSCLC. ASCO Annual Meeting. J Clin Oncol. 2012;30(Suppl):abstr TPS7613.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
14. He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs. 2014;32:577-86.
15. Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993;11:2150-7.
16. Infinity Pharmaceuticals, Inc. Infinity reports topline data from phase 2 study of retaspimycin hydrochloride, its Hsp90 inhibitor, in patients with non-small cell lung cancer. (press release, Sept 25, 2013). http://phx.corporateir. net/phoenix.zhtml?c=121941&p=irolnewsArticle& ID=1857866&highlight=
17. Inoue M, Koga F, Yoshida S, Tamura T, Fujii Y, Ito E, et al. Significance of erbB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach. Int J Radiat Oncol Biol Phys. 2014;90:303- 11.
18. Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS- 1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res. 2012;18:5090-8.
19. Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 2014;14:154-60.
20. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425:407-10.
21. Koga F, Kihara K. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Int J Urol. 2012;19:388-401.
22. Koga F, Yoshida S, Kawakami S, Kageyama Y, Yokoyama M, Saito K, et al. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-totreat survival analysis. Urology. 2008;72:384-8.
23. Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res. 2009;29:797-807.
24. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. ErbB2 and NFkappaB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscleinvasive bladder cancer. PLoS One. 2011;6:e27616.
25. Koga F, Kihara K, Yoshida S, Yokoyama M, Saito K, Masuda H, et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int. 2012;109:860-6.
26. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010;24:699-705.
27. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am. 2000;27:1-13, vii.
28. National Cancer Institute. Clinical Trials Search. 2014a. http://www.cancer.gov/clinicaltrials/search/results?pr otocolsearchid=12897579.
29. National Cancer Institute. SEER Stat Fact Sheets: Bladder Cancer. (7/5 2014). 2014b. http://seer.cancer.gov/statfacts/html/urinb.html.
30. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185cerbB- 2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem. 1996;271:22796-801.
31. Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C, et al. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res. 2013;73: 7022-33.
32. Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, et al. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Res Treat. 2013;139: 107-13.
33. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci. 2007;32:517-30.
34. Neckers L, Trepel JB. Stressing the development of small molecules targeting HSP90. Clin Cancer Res. 2014;20:275-7.
35. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res. 2011;17: 1561-70.
36. Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, et al. A Phase II trial of 17-allylamino, 17- demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. 2012;30:341-9.
37. Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20:3061-71.
38. Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, et al. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17- (allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71:1345-55.
39. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-9.
40. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010;28:4953-60.
41. Sessa C, Sharma SK, Britten CD, Vogelzang NJ, Bhalla KN, Mita MM, et al. A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2009;27;3532.
42. Shipley WU, Prout GR, Jr., Einstein AB, Coombs LJ, Wajsman Z, Soloway MS, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987;258:931-5.
43. Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62-7; discussion 67-8.
44. Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 2014;9:1-20.
45. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013;19:3068-77.
46. Squibb BM. Phase 2 clinical trial of intravenous alvespimycin [KOS-1022] in patients with Her2 positive breast cancer. Clinical Trials.gov. NLM 2011 Identifier: NCT00780000. http://www.clinicaltrials. gov/ct2/show/NCT00780000.
47. Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA, Petrelli NJ, et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA. 1999; 96:15121-6.
48. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995;36:305-15.
49. Synta Pharmaceuticals. 2014. HDC Platform. (7/24 2014); http://www.syntapharma.com/hdc-platform.php.
50. Synta Pharmaceuticals. Corp. SP. Synta announces results from final analysis of the GALAXY-1 trial of ganetespib in NSCLC. 2014 (7/5 2014; http://phx.corporateir. net/phoenix.zhtml?c=147988&p=irolnewsArticle& ID=1928644&highlight=)
51. Tatokoro M, Koga F, Yoshida S, Kawakami S, Fujii Y, Neckers L, et al. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancerinitiating cells. Int J Cancer. 2012;131:987-96.
52. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537-49.
53. Tsutsumi S, Beebe K, Neckers L. Impact of heatshock protein 90 on cancer metastasis. Future Oncol. 2009;5:679-88.
54. Welch WJ, Feramisco JR. Purification of the major mammalian heat shock proteins. J Biol Chem. 1982; 257:14949-59.
55. Whitesell L, Lin NU. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim Biophys Acta. 2012;1823:756-66.
56. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761- 72.
57. Whitesell L, Shifrin SD, Schwab G, Neckers LM. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 1992;52:1721-8.
58. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90- pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 1994;91:8324-8.
59. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolonecontaining Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012;11:475-84.
60. Ying W, Chimmanamada D, Zhang J, Przewloka T, Jiang J, Lu G, et al. Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation. Cancer Res. 2014;74:1619.
61. Yoshida S, Koga F, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle. 2011;10:4291-9.